Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents
about
The molecular mechanism for nuclear transport and its application.Three-Dimensional Mapping of mRNA Export through the Nuclear Pore Complex.Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancerTargeting nuclear transporters in cancer: Diagnostic, prognostic and therapeutic potential.Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells.Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitorsSuppressing activity of tributyrin on hepatocarcinogenesis is associated with inhibiting the p53-CRM1 interaction and changing the cellular compartmentalization of p53 protein.Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.CRM1 Inhibitors for Antiviral Therapy.Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.Promising therapies in multiple myeloma.Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses.Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
P2860
Q33903391-44D1432D-072D-47CE-A9CF-C55F0B5A670CQ34774750-BFDCBD45-C8CC-47E4-A4A6-D73A1FDACECAQ35732942-9713C56C-72C2-47B2-B0BD-DCA95E3D6EFEQ35955008-34E0A85D-1B07-4652-B847-718373656A65Q36214313-EA2263B7-7BDD-4A6E-B9ED-61F0C0D07E17Q37203487-115672F9-B83A-4070-8B27-CA6DA68CB219Q37269298-FA206266-1A57-498F-8BFC-0E51AEF20E65Q37603441-A60AA20A-C866-4F14-BDA1-3B5B5B152A9FQ37684621-7F3AF65C-5E0B-4AE3-A419-CC7022635C4BQ38853857-728E2A42-4835-48DC-8AAC-B0FEC531CE44Q38881093-D8E7946C-C37F-478A-8ECF-3549642E8927Q38943877-D911755D-19B4-40B5-8DE9-25FF47FEB9D4Q39431526-28CDAACD-03EB-4CF8-8765-F815C5B922A5Q41087485-426E2D28-7B8A-4491-87EF-E520BD126DD9Q42581682-4396C47D-177B-4315-BC78-FEC90AEF7EB6Q42711622-71F1351C-ECD9-4D55-9C5A-5B31D78E5A03Q47549703-1B016AFC-332F-4968-814C-7E893957D8E5Q47754114-968E6B59-6882-4B9B-A1E0-87393110BA3BQ58774746-5F3607C9-1131-4AC5-A079-665C27863484
P2860
Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@ast
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@en
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@nl
type
label
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@ast
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@en
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@nl
prefLabel
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@ast
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@en
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@nl
P2093
P2860
P1476
Inhibition of CRM1-dependent n ...... cytotoxic and targeted agents
@en
P2093
Christopher L Cubitt
Daniel M Sullivan
Jana Dawson
Joel G Turner
Rachid Baz
P2860
P356
10.1016/J.SEMCANCER.2014.03.001
P577
2014-03-12T00:00:00Z